Telix Pharmaceuticals Ltd (ASX: TLX) shares are drifting higher on Tuesday, extending gains to 98% for the year to date.
Shares in the biopharmaceutical company are swapping hands less than 1% higher at $19.90 apiece at the time of publication.
Whilst there's been nothing market-sensitive from the company today, it did announce a number of executive changes as part of an "internal reorganisation".
Let's dive in.
Image source: Getty Images
New leadership announced at Telix
Telix shares are relatively flat today, but the business announced several new leadership changes as part of a broader reorganisation, as it "reflec[ts] its focus".
This reorganisation is designed to "align" operations across its four business units and sees new executives at several posts.
There are a few 3 and 4-letter acronyms to come, so bear with me.
Richard Valeix, now the former chief commercial officer (CCO), is now chief executive officer (CEO) of Telix Therapeutics.
He will spearhead the commercialisation of Telix's therapeutic pipeline, which includes candidates for prostate, kidney, and brain cancer.
Secondly, Kevin Richardson, previously CEO of Telix's Americas division, takes on the role of CEO of Telix Precision Medicine. He will lead the development of diagnostic tools and oversee operations in North America.
Meanwhile, Raphael Ortiz has been appointed CEO of Telix International, responsible for commercial activities across Europe, the Middle East, Africa (EMEA), Asia Pacific (APAC), and Latin America (LatAm).
Telix's Managing Director and the overall group CEO, Dr Christian Behrenbruch, emphasised the importance of these changes:
Telix is at an inflection point: momentum in our therapeutics business is growing, with prostate, kidney and brain cancer therapeutic candidates currently in, or advancing to, pivotal clinical trials. Precision medicine is our global commercialisation engine, to bring personalised, theranostic solutions to market and is underpinned by a growing manufacturing footprint that enables enhanced control over the supply chain.
Telix is evolving, and the revised business model reflects our differentiated position, harnessing the power of targeted radiation at every step of the patient journey.
FY24 earnings a mixed outcome for Telix shares
Aside from the management changes, the biopharma and radiopharmaceutical company also posted its FY24 earnings last week.
Telix shares dipped after the release of the company's half-year results, despite a strong period of growth from the business.
It reported a 65% increase in revenue, reaching $364 million.
Growth was underscored by strong sales of its prostate cancer imaging agent, Illuccix, in the US.
Net profit for the half-year was $30 million, a significant turnaround from the $14 million loss in the prior year.
After a brief sell off, shares have regained momentum. Telix shares first dipped to $19.18 in the days following. But they are now drifting back to their 3-month closing highs of $20.31.
Telix shares snapshot
Telix shares have performed tremendously well over the past 12 months. The stock is up more than 85% during that time, lifting around 3.5% in the past month alone.
Owning Telix shares provided a 75% advantage over the past year.
